We are pleased to share that last Friday marked an important milestone for Technophage with the End of Study of the TP-102 Phase 2b clinical trial.
We would like to sincerely thank our CRO partners, Principal Investigators, and hospital teams in the United States and India, and most importantly the study participants. We also thank everyone who has contributed to the development of TP-102 up to this point. Your dedication and collaboration were essential to achieving this milestone.
We now move into data analysis and preparation of the Clinical Study Report, while continuing our planning toward a Phase 3 study. Our focus remains on advancing this program with the aim of providing a meaningful treatment option for patients with infected diabetic foot ulcers.
As the end of the year approaches, we look ahead with focus and optimism.